Some DBV Technologies (EPA:DBV) Shareholders Have Taken A Painful 83% Share Price Drop
DBV Technologies S.A. (EPA:DBV) shareholders will doubtless be very grateful to see the share price up 43% in the last month. But only the myopic could ignore the astounding decline over three years. The share price has sunk like a leaky ship, down 83% in that time. So it's about time shareholders saw some gains. But the more important question is whether the underlying business can justify a higher price still.
We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
Check out our latest analysis for DBV Technologies
DBV Technologies wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
In the last three years, DBV Technologies saw its revenue grow by 9.8% per year, compound. That's a fairly respectable growth rate. So it's hard to believe the share price decline of 44% per year is due to the revenue. It could be that the losses were much larger than expected. If you buy into companies that lose money then you always risk losing money yourself. Just don't lose the lesson.
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
If you are thinking of buying or selling DBV Technologies stock, you should check out this FREE detailed report on its balance sheet.
A Different Perspective
We regret to report that DBV Technologies shareholders are down 32% for the year. Unfortunately, that's worse than the broader market decline of 11%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 24% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 2 warning signs for DBV Technologies (1 is a bit concerning!) that you should be aware of before investing here.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on FR exchanges.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
About ENXTPA:DBV
DBV Technologies
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
High growth potential with excellent balance sheet.
Similar Companies
Market Insights
Weekly Picks

When GPS fails: this small cap is fixing a $54B drone problem

Why Amdocs is a high conviction Buy for me?
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Recently Updated Narratives
Ryde Group Ltd (NYSE American: RYDE): A High-Growth Challenger in Asia’s Digital Mobility and Quick Commerce

Yum! Brands: A High-Quality Compounder With Continued Global Growth Potential

The Tiny Australian School Stock That Bought Back a Quarter of Itself While Nobody Was Looking
Popular Narratives

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
A wonderful business at reasonable price.

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.
Trending Discussion
As someone who has dealt directly with them as a CTO for a credit union, I have 8 years of horror stories about doing business with them. If there was any other competitor than could deliver 80% of Fiserv services, there would be a mad rush to migrate to them. They should thank their lucky stars they are a near monopoly. this industry is so ripe for a well funded competitor. Their integration of technology is awful, their ability to fix their own implementation screwups is sadly tragic. Sometimes they just silently kill support tickets without resolution and you never find out until you do a follow up inquiry. Why, because sometimes no one you are dealing with knows how to fix it and knows no one to ask for help. They can not meet their own implementation deadlines and sometimes there is no one on a technical team dealing with you that has any banking or credit union experience. The is an industry insider phrase when you meet other Fiserv customers called being "Fiserved". It means telling others of your worst stories of dealing with them. Ask around, all CTO's have some doozies.


